New Drug Cuts Severe Epilepsy Seizures by 90% in Kids

Freddie Truelove can now ski down mountains and swim in lakes, activities his mom Lauren never dreamed possible for her eight-year-old son.

Just months ago, Freddie experienced hundreds of seizures every day from Dravet syndrome, a severe form of epilepsy that affects about one in 15,000 babies. The constant fits put children at high risk for injury and death, making even simple outings feel impossible for families.

Now, thanks to a new drug called zorevunersen, Freddie has only a couple of seizures per week. "We now have a life we didn't ever think was possible," Lauren told BBC News from their home in Huddersfield. "Most importantly, it's a life that Freddie can enjoy."

The treatment works differently than previous epilepsy medications. Instead of just managing symptoms, it targets the underlying genetic cause. Dravet syndrome happens when a faulty gene prevents brain cells from making enough sodium channels needed for proper communication.

Doctors inject zorevunersen into the lower back, where it travels through spinal fluid to the brain. Once there, it helps ramp up production of the missing channels, allowing for healthier brain activity with fewer seizures.

Early trial results published in the New England Journal of Medicine show young patients experienced up to 90% fewer seizures. Eighty-one children and teens participated across hospitals in the UK and US, with 19 treated at Great Ormond Street, Sheffield Children's Hospital, the Royal Hospital for Children in Glasgow, and University College London.

"It is exciting. It's amazing," said Professor Helen Cross from UCL's Institute of Child Health. "With improvements, that gives them real hope that they are able to carry out more normal lives, particularly with their families."

The Ripple Effect

For families who've spent years managing constant medical crises, this breakthrough means more than fewer seizures. It means walking dogs together, climbing mountains, and watching their children experience childhood joys they thought were forever out of reach.

The treatment can be given safely to children as young as two years old. While more research is needed before it becomes widely available, ongoing trials are showing continued promise.

Galia Wilson, chair of trustees at Dravet Syndrome UK, sees the real impact every day. "We regularly see the devastating impact that this condition has on the lives of families," she said. "That's why we're so thrilled about these latest results."

Freddie and other young patients continue taking the medication as researchers gather more data over the coming years.

Families living with Dravet syndrome finally have something they haven't had in years: genuine hope for near-normal futures.